2100 results
Selected Clinical Trials of SGLT2 inhibitors in CVD and CKD
EMPA-REG OUTCOME - Empagliflozin lowered CV events
Clinical Trials of SGLT2 ... ASCVD; signal for SGLT2i ... risk; signal for SGLT2i ... outcomes trial in SGLT2i ... mcclaffertyMD #SGLT2
SGLT2 Inhibitors and Cardiovascular Pathophysiology

#SGLT2i #Inhibitors #Cardiovascular #Pathophysiology
SGLT2 Inhibitors ... Pathophysiology #SGLT2i
Patient factors influencing the selection Of glucose-lowering drugs Other than SGLT2i and metformin in T2D and
drugs Other than SGLT2i ... metformin in T2D and CKD ... receptor agonist SGLT2i ... , #KDIGO2020 #CKD ... Management in CKD
Definitions of AKI, CKD, AKD
Acute Kidney Injury (AKI):
 • Increase in SCr by 2 50% within
Definitions of AKI, CKD ... , AKD Acute Kidney ... Kidney Disease (CKD ... /CKD • No structural ... damage #AKI #CKD
Cardiovascular and renal effects comparison between SGLT-2 inhibitors
 - Canagliflozin (Invokana)
 - Dapagliflozin (Farxiga)
 - Empagliflozin
comparison between SGLT ... cardiovascular #renal #SGLT2i
Algorithmic Approach to Acute Interstitial Nephritis
When to suspect AIN? (not sensitive)
 • AKI, AKD, rapidly progressive
Algorithmic Approach ... sensitive) • AKI, AKD ... rapidly progressive CKD ... Nephritis #AIN #Algorithm
SGLT2 Inhibitors and Euglycemic DKA

Risk factors for euglycemic DKA in those on an SGLT2i include:
 •
SGLT2 Inhibitors ... in those on an SGLT2i ... is closed • SGLT2 ... Kat_Watson #SGLT2
How SGLT2 inhibitors block glucose reabsorption in proximal tubule and improve systemic glucose homeostasis:
https://www.ajkd.org/article/S0272-6386(18)30633-4/fulltext

#Pathophysiology #Mechanism #Nephrology
How SGLT2 inhibitors ... Mechanism #Nephrology #SLGT2
Diabetes Type 2 Medication Management and Titration Algorithm
- First line therapy is metformin and comprehensive lifestyle
and Titration Algorithm ... Established ASCVD or CKD ... established ASCVD or CKD ... Medication #Management #Algorithm
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
-4 inhibitors SGLT2 ... Improved outcomes in CKD